LysoPC(20:4)
|
Basic information |
| Metabolite name | LysoPC(20:4) |
 | N/A |
 |
C04230 |
 |
N/A |
| Synonyms | NA |
| No. of studies | 16 |
|
Basic information |
| Metabolite name | LysoPC(20:4) |
| N/A |
|
C04230 |
|
N/A |
| Synonyms | NA |
| No. of studies | 16 |
|
Relationship between LysoPC(20:4) and depression (count: 16) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M095 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M096 | Type1 | CUMS group vs. control group | Plasma | Wistar rat | Up |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | Serum | ICR mouse | Up |
| Study M1117 | Type1 | MDD group vs. control group, Russian cohort | Plasma | Human | Down |
| Study M120 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M122 | Type3 | maprotiline group vs. control group | Prefrontal cortex | BALB/c mouse | Up |
| Study M123 | Type3 | rTMS group vs. control group | Prefrontal cortex | Wistar rat | Up |
| Study M124 | Type3 | maprotiline group vs. control group | Prefrontal cortex | BALB/c mouse | Up |
| Study M457 | Type3 | D6 doses of PBR group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M582 | Type1 | CUMS group vs. control group | Serum | C57BL/6N mouse | Down |
| Study M582 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | C57BL/6N mouse | Down |
| Study M582 | Type3 | control + fluoxetine group vs. control group | Serum | C57BL/6N mouse | Down |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Serum | C57BL/6 J mouse | Up |
| Study M690 | Type2 | CUMS + high dose of Zhi-zi-chi decoction group vs. CUMS group | Serum | Balb/c mouse | Up |
| Study M743 | Type1 | CUS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M775 | Type1 | prenatal stress group vs. control group | Brain | Swiss Webster mouse | Down |
| Study M789 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M789 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M789 | Type2 | CUMS + liquiritin group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M890 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |